Dynavax is a clinical-stage biopharmaceutical company with multiple product candidates in development for the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The company’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine; and AZD1419, which is in Phase II clinical trial for the treatment of asthma. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.